← Home

MSB

Healthcare & BiotechPULLBACK

$2.220

as of 2026-09-09

5d return

-6.3%

20d return

-7.5%

60d return

+12.4%

RSI 14

29.6

vs 52w high

-27.7%

vs 52w low

+17.8%

SMA 20

Below

SMA 50

Below

Price · Volume · Broker flow
Markers = announcements (red triangle = price-sensitive). Volume amber = ≥2× ADV spike.
Loading chart…
Closest correlates
Pearson r on log returns, window: 82d
  • 4DXr=0.46, window: 82d
  • WAUr=0.43, window: 82d
  • CU6r=0.42, window: 82d
  • GT1r=0.38, window: 82d
  • SHNr=0.37, window: 82d
Announcements — last 30 days
  • 2026-08-27PSotherMSB Annual Financial Results and Operational Update

    (interpretation unavailable)

  • 2026-08-27PSmre_updatePreliminary Final Report including Appendix 4E

    Mesoblast's FY26 annual report filing (Form 20-F/Appendix 4E) confirms accelerated filer status and large-cap positioning on NASDAQ, but zero cash on hand indicators tight liquidity and potential near-term capital needs for a clinical-stage biotech. Retail inflows (+$7.2m vs negligible institutional) suggest retail accumulation into a pre-announcement 20d rally (+16%) now stalled.